Stem cells

This is the latest episode of the free narrated DDW podcast, “Is customisation healthcare’s secret weapon?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW. The articles are called “Optimising vaccine production through customisation” and “Exploring iPSCs for individual and population health applications”.  In the first article, “Optimising vaccine […]

Human Cell Design, a biotechnology company focused on generating translational human cellular models, has launched Endoc-BH5 to “open up entirely new scientific avenues in diabetes studies”, the company says.   What is Endoc-BH5?  Human Cell Design combined hiPSC-derived differentiated cells (human-induced Pluripotent Stem Cells) and primary cell models with its proprietary NatLine amplification and maturation platform […]

Bone Therapeutics and Implant Therapeutics have signed a research evaluation agreement to enable Bone Therapeutics to access, evaluate and materially transfer Implant Therapeutics’ Induced Pluripotent Stem Cell (iPSC) lines, media, differentiation protocols and expertise.  Bone Therapeutics has developed a bone marrow-derived off-the-shelf, allogeneic MSC cell therapy platform. Its allogeneic cell therapy product, ALLOB, currently in […]

Listen to this article on the DDW Podcast: Brad Hamilton, Founder and Chief Science Officer at GoodCell examines the potential of induced Pluripotent Stem Cells. Across the world, patients suffering from heart failure, donor organ rejection and many other life-altering illnesses are struggling to combat the symptoms of their conditions. What if there was a way […]

Listen to this article on the DDW Podcast: Pierre-Louis Joffrin leads Corporate Development at Mogrify. He examines immunotherapies including an assessment of the next generation of stem cell derived products. Biotech has joined the pursuit of next-generation CAR-Ts and it’s not subtle. Some new, others having pivoted towards the area, there are now over 100 companies […]

BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421. BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the potential to repair damage caused […]

Tiny 3-D models that mimic vital aspects of the human nervous system have been developed in a step that could accelerate drug research for neurological conditions such as multiple sclerosis (MS). The millimetre-wide models – created using stem cells from human skin samples – will be used to study myelin, an insulating substance that helps […]

Today’s episode is titled: The power of precision and the potential of human tissue chips, and covers 2 articles taken from the most recent issue of DDW. These articles are titled: The power of precision to keep biologics effective and safe & Why we should be interested in human tissue chips These articles were written by Dr Mark […]

iotaSciences, a company that develops technologies for single-cell cloning is giving exhibitor tutorials at SLAS2021 Digital. These tutorials will explore some of the key challenges of single-cell cloning for gene editing, stem cells and other applications. During the tutorials we will introduce our new cloning platform and provide customer data which demonstrates cloning efficiencies of […]

REPROCELL’s new service – Personal iPS – will generate individual specific induced pluripotent stem cells (iPSC). The company will start taking orders from this month (January 2021) in Japan and has also launched a new B2C website to promote this service, which is currently only available in Japan. Personal iPS prepares and stores an individual’s […]